Boston Scientific Corp (BSX)vsBlackstone Group Inc (BX)
BSX
Boston Scientific Corp
$53.93
-4.67%
HEALTHCARE · Cap: $84.08B
BX
Blackstone Group Inc
$123.77
+1.18%
FINANCIAL SERVICES · Cap: $149.52B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 43% more annual revenue ($20.61B vs $14.40B). BX leads profitability with a 21.2% profit margin vs 17.3%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).
BSX
Strong Buy71
out of 100
Grade: B
BX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.6%
Fair Value
$46.16
Current Price
$53.93
$7.77 premium
Intrinsic value data unavailable for BX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Strong operational efficiency at 20.6%
Strong operational efficiency at 38.0%
Large-cap with strong market position
Every $100 of equity generates 30 in profit
Keeps 21 of every $100 in revenue as profit
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 11.6x book value
3.9% earnings growth
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : BX
The strongest argument for BX centers on Operating Margin, Market Cap, Return on Equity. Profitability is solid with margins at 21.2% and operating margin at 38.0%.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : BX
The primary concerns for BX are PEG Ratio, P/E Ratio, Price/Book. Debt-to-equity of 1.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
BX carries more volatility with a beta of 1.63 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BX generates stronger free cash flow (958M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BSX scores higher overall (71/100 vs 61/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Blackstone Group Inc
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
Blackstone Group Inc. is an alternative asset management company specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity strategies and multiple asset classes. The company is headquartered in New York, New York with additional offices across Asia, Europe and North America.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?